Healthcare Professionals
Please log in for special information and services
Khalil Nassib Wehbe Country Manager Gulf Region

“Our team at AOP Orphan Pharmaceuticals FZ-LLC implements international strategies according to both local and global considerations. We boost AOP Orphan market presence by working closely with leading health care professionals and are dedicated to continuously supporting the best quality of life for patients with rare diseases!’

Facts & Figures

AOP Orphan is fully dedicated to pharmaceutical and clinical development as well as commercialisation of drugs for more than 20 years already.

Our motivation at AOP Orphan is to help patients who suffer from rare diseases. We achieve this cooperating with stakeholders of the Middle East health care system. Partnerships within pharmaceutical and health care industry are crucial for finding and providing solutions for patients, especially in the treatment of orphan diseases. 

AOP Orphan Middle East was established in Dubai, UAE in September 2009 and transformed to FZ-LLC in 2017 to provide vitally important therapeutic drugs for specialized indications in the areas of HematoOncology, Neurology and Metabolic Disorders, covering the Gulf Region as well as the Middle East, North Africa and Asia.

AOP Orphan Pharmaceuticals FZ- LLC is a team of dedicated employees based in the United Arab Emirates Free zone, with a strong focus and specialization on marketing, sales and distribution of medicines for rare, orphan and complex diseases.

 

2.8m
people
rare disease patients
Whether a disease is defined as a rare disease depends on the frequency of its occurrence in the population. It is estimated that 2.8 million patients suffer from a rare disease in the Middle East region. 
available treatments
In the Middle East region AOP Orphan provides two innovative products and treatments. 

 
2
products
2
areas
Two THERAPEUTIC AREAS
AOP Orphan covers two treatment areas: HematoOncology, Neurology and Metabolic Disorders in the Middle East region.

Vision & Mission

Milestones

History of more than 20 years means many significant milestones — in research,  social, business spheres and regulatory affairs — that were and are important for AOP Orphan.

1996

Foundation of AOP Orphan in Vienna

1999

The Orphan Regulation EC no 141/2000

2001

1st Approval of Anagrelide in Europe

2004

European Union Expansion

2005

Prostacyclin Analogues Approval

2005

JAK2 Discovery

2008

Renaissance of Interferon (IFNα)

2010

UDCA Designation

2010

Tetrabenazine Approval in Central Europe

2012

Nabilone Approval in Austria

2013

Start of the PROUD PV Study

2015

Beta-blocker for severe sepsis

2016

Pitolisant approval

2017

Landiolol approval

2018

Treprostinil and PAH

2019

BESREMi® Approval

Corporate culture

Thanks to many years of experience in the provision of complex and individualized treatments, AOP Orphan gained special expertise and market presence in the field of rare diseases.

Since its very start AOP Orphan has borne the social responsibility of further life quality improvement for patients with severe, rare and life-threatening diseases. We at AOP Orphan conduct intensive research for this purpose, believing that developing and providing solutions for patients is the most important part of the AOP Orphan corporate responsibility. When it comes to wanting the best for the patients, we stand side-by-side with each other as a team, with researches, physicians, therapists, caregivers, patient organizations and other stakeholders. 

AOP Orphan is keen to keep one of its greatest assets – it is closely networked with the key specialists in all markets and is therefore able to help patients with rare diseases from Austria throughout the world.

Mag. Andreas Steiner Group CEO AOP Orphan International AG

From its inception AOP Orphan's culture is shaped by the entrepreneurial spirit of its founder. We are proud to be a company that encourages employees to come up with new ideas and to show ownership and initiative every day. To help neglected patients with rare diseases is our key motivator. Through close interaction with the scientific community, care givers and partners we aim to provide therapies and help patients beyond just providing drugs.

The future

Thanks to our advancements in the field of therapies, an increasing number of patients survive their disease or are able to live with it for a longer period of time. In the next few decades, personalized medicine, individual treatment opportunities will emerge more and more as the standard in AOP Orphan’s therapy concepts as well.

Novel technologies such as next-generation sequencing (NGS) will play an equally crucial role as the increasing quantities of big data and conclusions derived from the daily lives of patients also beyond the strictly regulated conditions of clinical trials, e.g. real-world evidence.

Furthermore, the increasing health competence, health literacy of patients and their family members will also determine the future of pharma and health care sector.